Lucid Diagnostics Inc. (LUCD)
Nasdaq · Healthcare · Medical Devices
$0.5933−5.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $113M
- 52-week range
- $0.50 – $1.63
- 52-week change
- −39.13%
- EPS (trailing)
- −$0.42
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $4.7M (+8.28%)
- Net income
- −$58.0M
- Operating margin
- −1054.8%
- Free cash flow
- −$46.7M
From the company’s annual report on SEC EDGAR.
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Headquarters: New York, United States · 82 employees · luciddx.com